RxDoctor Payments DataLook up a doctor →

Stephen Aronoff, MD

Endocrinology, Diabetes & Metabolism · Richardson, TXNPI 1538106844

Payments from drug & device makers

$1,775,721in general payments, 2019–2025

Across 1,766 payments — averaging $1005.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$617K
  • Novo Nordisk AS$565K
  • Amgen$178K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$125K
  • Boehringer Ingelheim International GmbH$66K
  • Sanofi US Services Inc.$64K
  • plus $162K from 54 others
$763in research payments, 2019–2025

Across 3 payments — averaging $254.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$763

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly25$617,032
Novo Nordisk AS470$564,587
Amgen304$177,702
Boehringer Ingelheim Pharma GmbH & Co.kg60$124,790
Boehringer Ingelheim International GmbH24$66,250
Sanofi US Services Inc.80$63,573
Dexcom, Inc.19$54,063
Kowa Research Institute, Inc.20$25,812
Janssen Research & Development, LLC9$22,261
Pfizer12$18,894
AstraZeneca(2 entities)91$13,860
AbbVie61$7,972
Tandem Diabetes Care, Inc.27$7,350
Boehringer Ingelheim France S.a.s.5$2,016
Novo Nordisk99$1,358
Lilly USA, LLC55$1,187
Kvk-tech, Inc.31$638
Insulet Corporation20$594
Amarin Pharma, Inc.32$449
Boehringer Ingelheim19$327
Eisai Inc.22$319
Mannkind Corporation17$286
Merck21$280
Esperion Therapeutics, Inc.19$259
Xeris Pharmaceuticals, Inc.15$259
Radius Health, Inc.14$258
Corcept Therapeutics10$218
Bayer12$195
Sanofi-aventis U.S. LLC11$182
Amneal Pharmaceuticals LLC10$170
Intuity Medical Inc10$168
Idorsia Pharmaceuticals US Inc9$158
Currax Pharmaceuticals LLC11$154
Ascendis Pharma Endocrinology Inc7$140
Kowa Pharmaceuticals America, Inc.9$127
Verity Pharmaceuticals Inc.6$126
Abbott2$123
Antares Pharma, Inc.8$122
Novartis7$117
IBSA Pharma Inc.8$107
Zealand Pharma US, Inc.5$85
Clarus Therapeutics Inc.6$72
Takeda Pharmaceuticals U.S.A., Inc.4$72
Ascensia Diabetes Care US Inc.5$71
Recordati_rare_diseases_inc.2$69
Madrigal Pharmaceuticals3$64
Sequel Med Tech, LLC3$62
Avvisto Therapeutics, LLC4$62
Ultragenyx Pharmaceutical Inc.3$58
BETA Bionics, Inc.4$57
Vivus LLC4$49
Neurocrine Biosciences, Inc.2$49
Tolmar, Inc.2$45
Boston Scientific2$34
Genentech USA, Inc.2$31
Acerus Pharmaceuticals Corporation2$29
Ferring Pharmaceuticals Inc.2$27
Gilead1$27
Johnson & Johnson2$27
Kyowa Kirin, Inc.1$26

How this compares

$1,775,721 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Medicare billing

Part B allowed, 2024
$68,721
Medicare patients
211
Services billed
8,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Richardson

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →